Sanofi secures $43 million government funding for zika vaccine development
pharmafile | September 27, 2016 | News story | Manufacturing and Production, Research and Development | BARDA, Sanofi, Zika
The US Department of Health and Human Services approved $43.18 million to fund Sanofi’s development of a zika vaccine, the company has announced.
The firm’s vaccine unit, Sanofi Pasteur, voiced its intention to develop a vaccine in collaboration with the government in June. The funding comes from the BioMedical Advanced Research and Development Authority (BARDA) and runs until June 2022 and will be used to pursue mid-stage trials beginning in 2018; an additional $130.45 is contracted for later-stage trials in the event that the data generated is positive.
Takeda recently secured $312 million from the same authority to work on a zika vaccine and GSK has also gone on record with an interest to join the development race.
Matt Fellows
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …






